Published in J Biol Chem on June 18, 2013
Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy. Drugs (2014) 0.94
Opposing effects of target overexpression reveal drug mechanisms. Nat Commun (2014) 0.90
Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 0.88
Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012. Antimicrob Agents Chemother (2014) 0.88
Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2015) 0.85
Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2015) 0.85
Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation. PLoS One (2015) 0.84
Serum protein gamma-glutamyl hydrolase, Ig gamma-3 chain C region, and haptoglobin are associated with the syndromes of pulmonary tuberculosis in traditional Chinese medicine. BMC Complement Altern Med (2015) 0.81
Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance. Antimicrob Agents Chemother (2015) 0.81
Antibiotic resistance mechanisms in M. tuberculosis: an update. Arch Toxicol (2016) 0.80
Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing polypharmacological target selection. Sci Rep (2014) 0.80
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother (2014) 0.80
New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. Front Microbiol (2017) 0.79
A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis. ACS Infect Dis (2015) 0.77
dfrA thyA Double Deletion in para-Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains. Antimicrob Agents Chemother (2016) 0.77
Mycobacterium tuberculosis metabolism. Cold Spring Harb Perspect Med (2014) 0.76
Mycobacterium tuberculosis Arylamine N-Acetyltransferase Acetylates and Thus Inactivates para-Aminosalicylic Acid. Antimicrob Agents Chemother (2016) 0.75
Anti-folates potentiate bactericidal effects of other antimicrobial agents. J Antibiot (Tokyo) (2017) 0.75
Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro. Antimicrob Agents Chemother (2017) 0.75
Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates. Sci Rep (2016) 0.75
Antimycobacterial Metabolism: Illuminating Mycobacterium tuberculosis Biology and Drug Discovery. Trends Microbiol (2017) 0.75
Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol (2003) 16.82
New use of BCG for recombinant vaccines. Nature (1991) 14.40
Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology (2002) 6.20
Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology (2000) 5.00
The Tuberculostatic Action of para-Aminosalicylic Acid. J Bacteriol (1947) 3.57
Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science (2002) 2.65
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun (2010) 2.49
Dihydrofolate reductase as a therapeutic target. FASEB J (1990) 1.92
Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nat Struct Biol (1997) 1.86
Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother (2009) 1.84
THE ENZYMATIC SYNTHESIS OF FOLATE-LIKE COMPOUNDS FROM HYDROXYMETHYLDIHYDROPTERIDINE PYROPHOSPHATE. J Biol Chem (1964) 1.78
Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci U S A (2011) 1.54
Biosynthesis of riboflavin, folic acid, thiamine, and pantothenic acid. Adv Enzymol Relat Areas Mol Biol (1982) 1.45
Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science (2012) 1.44
The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol (2004) 1.43
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2009) 1.33
The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew Chem Int Ed Engl (2011) 1.29
Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog (2011) 1.29
Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother (2008) 1.28
Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol (2000) 1.27
Mycobacterium tuberculosis and sulfamethoxazole susceptibility. Antimicrob Agents Chemother (2010) 1.24
Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother (2002) 1.16
Para-aminosalicylic acid in the treatment of tuberculosis. Lancet (1946) 1.14
Escherichia coli FolC structure reveals an unexpected dihydrofolate binding site providing an attractive target for anti-microbial therapy. J Biol Chem (2005) 1.06
Plasmodium falciparum: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase. Exp Parasitol (1997) 1.05
Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli. J Bacteriol (1999) 1.03
Inhibition of mycobactin formation in Mycobacterium smegmatis by p-aminosalicylate. A new proposal for the mode of action of p-aminosalicylate. Am Rev Respir Dis (1972) 0.89
Structures of Mycobacterium tuberculosis folylpolyglutamate synthase complexed with ADP and AMPPCP. Acta Crystallogr D Biol Crystallogr (2008) 0.89
Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol Lett (2008) 0.88
Development of a novel Gateway-based vector system for efficient, multiparallel protein expression in Escherichia coli. Protein Expr Purif (2008) 0.86
Crystal structure of a bifunctional deaminase and reductase from Bacillus subtilis involved in riboflavin biosynthesis. J Biol Chem (2005) 0.86
A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 44.81
Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A (2002) 25.47
Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol (2003) 16.82
Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol (2006) 12.53
Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A (2003) 9.15
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol (2009) 8.13
A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc Natl Acad Sci U S A (2002) 5.70
Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science (2010) 5.50
Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci U S A (2005) 4.43
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
Expression analysis of G Protein-Coupled Receptors in mouse macrophages. Immunome Res (2008) 3.54
Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis (2003) 3.52
Drosophila RNAi screen reveals CD36 family member required for mycobacterial infection. Science (2005) 3.49
Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature (2008) 3.39
Genome-wide RNAi screen for host factors required for intracellular bacterial infection. Science (2005) 3.28
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A (2008) 3.13
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci U S A (2007) 3.06
In situ proteolysis for protein crystallization and structure determination. Nat Methods (2007) 3.05
Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc Natl Acad Sci U S A (2007) 3.05
Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol (2008) 2.97
Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol (2002) 2.94
The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2008) 2.92
Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci U S A (2010) 2.62
Illumination of the melanopsin signaling pathway. Science (2005) 2.58
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun (2010) 2.49
Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol (2007) 2.46
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant (2004) 2.35
Gene set enrichment in eQTL data identifies novel annotations and pathway regulators. PLoS Genet (2008) 2.32
Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 2.31
Characterization of mycobacterial virulence genes through genetic interaction mapping. Proc Natl Acad Sci U S A (2006) 2.29
Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol (2009) 2.22
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med (2013) 2.19
Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis (2009) 2.15
Construction of a mariner-based transposon for epitope-tagging and genomic targeting. Gene (2002) 2.15
Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci U S A (2009) 2.10
Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J Immunol (2004) 2.08
Identification of the circadian transcriptome in adult mouse skeletal muscle. Physiol Genomics (2007) 2.06
Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med (2011) 2.06
Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev (2008) 2.01
Genomewide association analysis in diverse inbred mice: power and population structure. Genetics (2007) 2.01
Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell (2013) 1.96
Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog (2009) 1.96
Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet (2013) 1.93
Twin RNA polymerase-associated proteins control virulence gene expression in Francisella tularensis. PLoS Pathog (2007) 1.92
Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell (2007) 1.90
Global assessment of genomic regions required for growth in Mycobacterium tuberculosis. PLoS Pathog (2012) 1.85
Architecture of Eph receptor clusters. Proc Natl Acad Sci U S A (2010) 1.82
Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein. J Biol Chem (2011) 1.79
Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes. Proc Natl Acad Sci U S A (2010) 1.74
A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol (2010) 1.72
Mycobacterium abscessus activates the NLRP3 inflammasome via Dectin-1-Syk and p62/SQSTM1. Immunol Cell Biol (2011) 1.69
Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol (2010) 1.66
Extinction training regulates neuroadaptive responses to withdrawal from chronic cocaine self-administration. Learn Mem (2004) 1.63
CLOCK and BMAL1 regulate MyoD and are necessary for maintenance of skeletal muscle phenotype and function. Proc Natl Acad Sci U S A (2010) 1.63
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics (2007) 1.60
Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology (2009) 1.60
Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog (2012) 1.60
A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 1.59
Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). J Biol Chem (2006) 1.59
A partner for the resuscitation-promoting factors of Mycobacterium tuberculosis. Mol Microbiol (2007) 1.59
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2005) 1.55
Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci U S A (2011) 1.54
Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet (2013) 1.54
The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol (2006) 1.52
Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci U S A (2013) 1.51
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother (2011) 1.51
Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis (2002) 1.50
Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med (2004) 1.47
A mycobacterial enzyme essential for cell division synergizes with resuscitation-promoting factor. PLoS Pathog (2008) 1.47
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) (2012) 1.47
Sensitive profiling of chemically diverse bioactive lipids. J Lipid Res (2007) 1.45
Molecular and epidemiological evidence for spread of multiresistant methicillin-susceptible Staphylococcus aureus strains in hospitals. Antimicrob Agents Chemother (2007) 1.45
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. PLoS Pathog (2010) 1.45
The biology of Ku and its potential oncogenic role in cancer. Biochim Biophys Acta (2006) 1.44
A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A (2007) 1.44
Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol (2004) 1.44
The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol (2004) 1.43
A strategy for modulation of enzymes in the ubiquitin system. Science (2013) 1.43
Persistence of a highly resistant strain of tuberculosis in New York City during 1990-1999. J Infect Dis (2003) 1.41
A phosphorylated pseudokinase complex controls cell wall synthesis in mycobacteria. Sci Signal (2012) 1.41
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety (2004) 1.38